Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220856834> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4220856834 endingPage "313" @default.
- W4220856834 startingPage "305" @default.
- W4220856834 abstract "Introduction: This study analyzes the safety and efficacy results of the Indian population subset from the RECLAIM trial investigating the non-inferiority of Ceftazidime-Avibactam (CAZ-AVI) plus metronidazole to meropenem and interprets its relevance.
 Methodology: The study design, subjects inclusion criteria, dosage, safety and efficacy evaluations in Indian patients have been followed as per the RECLAIM trial protocol.
 Results: A total of 142 Indian patients with complicated intra-abdominal infection were enrolled across eight centers in India, 125 of them were randomized to either CAZ-AVI + metronidazole (n = 62) or meropenem (n = 63) group. the clinical cure rates in modified intention-to-treat (MITT; all randomized patients who met minimum disease requirements and received any amount of study drug) and clinically evaluable (CE , patients who had an evaluable assessment and no protocol deviations) analysis sets, was numerically comparable to the results of overall population for CAZ-AVI + metronidazole [MITT: 82.5% (Overall, n = 429/520) versus 89.3% (Indian, n = 50/56); CE: 91.7% (Overall, n = 376/410) versus 97.8% (Indian, n = 45/46)] and meropenem [MITT: 84.9% (Overall, n = 444/523) versus 84.7% (Indian, n = 50/59); CE: 92.5% (Overall, n = 385/416) versus 95.5% (Indian, n = 42/44)]. No new safety findings were reported in the Indian population.
 Conclusions: CAZ-AVI + metronidazole proved to be an effective option for critical patients with complicated intra-abdominal infection and can be considered as an alternative to carbapenems in the ICU setting for the treatment of resistant pathogens." @default.
- W4220856834 created "2022-04-03" @default.
- W4220856834 creator A5064720301 @default.
- W4220856834 creator A5073306569 @default.
- W4220856834 creator A5075353586 @default.
- W4220856834 date "2022-02-28" @default.
- W4220856834 modified "2023-10-14" @default.
- W4220856834 title "Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM" @default.
- W4220856834 doi "https://doi.org/10.3855/jidc.14912" @default.
- W4220856834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35298426" @default.
- W4220856834 hasPublicationYear "2022" @default.
- W4220856834 type Work @default.
- W4220856834 citedByCount "2" @default.
- W4220856834 countsByYear W42208568342022 @default.
- W4220856834 countsByYear W42208568342023 @default.
- W4220856834 crossrefType "journal-article" @default.
- W4220856834 hasAuthorship W4220856834A5064720301 @default.
- W4220856834 hasAuthorship W4220856834A5073306569 @default.
- W4220856834 hasAuthorship W4220856834A5075353586 @default.
- W4220856834 hasBestOaLocation W42208568341 @default.
- W4220856834 hasConcept C126322002 @default.
- W4220856834 hasConcept C141071460 @default.
- W4220856834 hasConcept C168563851 @default.
- W4220856834 hasConcept C2775933652 @default.
- W4220856834 hasConcept C2776968632 @default.
- W4220856834 hasConcept C2777396551 @default.
- W4220856834 hasConcept C2777637488 @default.
- W4220856834 hasConcept C2779375183 @default.
- W4220856834 hasConcept C2908647359 @default.
- W4220856834 hasConcept C501593827 @default.
- W4220856834 hasConcept C523546767 @default.
- W4220856834 hasConcept C54355233 @default.
- W4220856834 hasConcept C71924100 @default.
- W4220856834 hasConcept C86803240 @default.
- W4220856834 hasConcept C89423630 @default.
- W4220856834 hasConcept C90924648 @default.
- W4220856834 hasConcept C94665300 @default.
- W4220856834 hasConcept C99454951 @default.
- W4220856834 hasConceptScore W4220856834C126322002 @default.
- W4220856834 hasConceptScore W4220856834C141071460 @default.
- W4220856834 hasConceptScore W4220856834C168563851 @default.
- W4220856834 hasConceptScore W4220856834C2775933652 @default.
- W4220856834 hasConceptScore W4220856834C2776968632 @default.
- W4220856834 hasConceptScore W4220856834C2777396551 @default.
- W4220856834 hasConceptScore W4220856834C2777637488 @default.
- W4220856834 hasConceptScore W4220856834C2779375183 @default.
- W4220856834 hasConceptScore W4220856834C2908647359 @default.
- W4220856834 hasConceptScore W4220856834C501593827 @default.
- W4220856834 hasConceptScore W4220856834C523546767 @default.
- W4220856834 hasConceptScore W4220856834C54355233 @default.
- W4220856834 hasConceptScore W4220856834C71924100 @default.
- W4220856834 hasConceptScore W4220856834C86803240 @default.
- W4220856834 hasConceptScore W4220856834C89423630 @default.
- W4220856834 hasConceptScore W4220856834C90924648 @default.
- W4220856834 hasConceptScore W4220856834C94665300 @default.
- W4220856834 hasConceptScore W4220856834C99454951 @default.
- W4220856834 hasIssue "02" @default.
- W4220856834 hasLocation W42208568341 @default.
- W4220856834 hasLocation W42208568342 @default.
- W4220856834 hasOpenAccess W4220856834 @default.
- W4220856834 hasPrimaryLocation W42208568341 @default.
- W4220856834 hasRelatedWork W2153512397 @default.
- W4220856834 hasRelatedWork W2294833633 @default.
- W4220856834 hasRelatedWork W2602847039 @default.
- W4220856834 hasRelatedWork W2890203079 @default.
- W4220856834 hasRelatedWork W2961303957 @default.
- W4220856834 hasRelatedWork W2995210052 @default.
- W4220856834 hasRelatedWork W4220856834 @default.
- W4220856834 hasRelatedWork W4241745679 @default.
- W4220856834 hasRelatedWork W4252680959 @default.
- W4220856834 hasRelatedWork W4317470343 @default.
- W4220856834 hasVolume "16" @default.
- W4220856834 isParatext "false" @default.
- W4220856834 isRetracted "false" @default.
- W4220856834 workType "article" @default.